Free Redacted Document - District Court of Delaware - Delaware

U Case 1 :O4—cv—OO171-GI\/IS Document 69-9 Filed O9/28/2005 Page 1 of 3
Morgan, L is & Buckles up '
I wt elitist Morgan Lewis
iixvgggaggigggggnucsu COUNSELOIS AT LAW
I Fax: 2t2.309.600!
www.morgan§ewis.c¤m
Thomas J. Puppa
212-309-2118
l tpuppa@m¤rganlsuds,com
n June 6, 2005
i VIA FACSHVIILE
John M. Bems, Esq.
Merchant & Gould
I 3200 IDS Center
80 South Eighth Street
Minneapolis, MN 55402
U Re: Glaxo Group Limited v. T eva Pharmaceuticals USA, Inc. and Teva Pharmaceutical
Industries Limited, Civil Action No. 04-171-KA}
l Dear John:
At the recent depositions of Tamas Szederkenyi and Leslie Kyle requests were made on the
I record for documents identified bythe witnesses. I am writing to request again that these
documents be produced as soon as possible.
The following general descriptions of documents were identified and requested during the
deposition of Mr. Szederkenyi:
i • inventory records of documents collected (page 50, lines 4-8);
• Szederkenyi, Analytical Research and Development, Pharmaceutical Development, and
Novopharrn e-mails regarding ranitidine hydrochloride oral solution {pate 63, lines 17-
I 24);
• index of laboratory notebooks (page 75, lines 1-6);
I • organizational charts (page 98, line 24 to page 99, line ll);

“ Case 1 :04-cv-OO171-GIVIS Document 69-9 Filed O9/28/2005 Page 2 of 3
I Morgan Lewis
MmkD_SchuH;&n,Esq_ eouxutons ar nav
June 6, 2005
I Page 2 .
I • list or catalog of stability testing methods (page 103, lines 6-10);
• documentation sufficient to identify the formula that is lot 91043 (page 106, lines 5·8);
n • lab notebooks numbers 7427, 7452, 7473, 8328, and 8386 andthe lab notebook numbers
on page T7580 (page 136, lines 4-16);
l • preformulation infomation package (page 142, lines 2—4);
,;, , • the entire file that was transferred from Novopharm to Teva regarding stability and any
other testing that was done (page 150, lines 16-20); and
• Novopharrn development reports identified on T2597 (page 153, lines 10-15).
i The following general descriptions of documents were identified and requested during the
deposition of Mr. Kyle:
R • pages relating to ranitidine oral solution from the lab notebook marked as Exhibit 13,
bates nos. T6573-6591 (page 93, lines 8-19);
I • any documents relating to list number 6127 (page 97, lines 9-14);
• identity of person in Process Engineering assigzed to the ranitidine oral solution project
I (page 109, line 21 to page 110, line 2};
• signed copy of Exhibit 15 (page 116, lines 9-11);
! • protocols relating to ranitidine oral solution (page 147, line 23 to page 148, line 2);
• stability tests done by Quality Control or Quality Assurance on any ranitidine oral
solution samples (page 150, lines 9-13);
• anything relating to ranitidine oral solution contained on the “N” drive (page 154, lines
i 20-25);
• Mr. Kyle’s computer tiles relating to ranitidine oral solution (page 156, lines 11-16);
I • earlier version of Exhibit 20 (page 163, lines 19-21);
I • notebooks identified in Exhibit 21 to the extent not previously produced (page 172, lines
4-12);

U Case 1 :04-cv-OO171-GIVIS Document 69-9 Filed O9/28/2005 Page 3 of 3
Morgan Lewis
MerkD.Schuman,Esq. couusntcxs AT LA!
Jtme 6, 2005
I ?age 3
I • stability tests of Glaxtfs Zaritsc syrup to the extent not previously produced (page 174,
lines il-i6); and
I • all documents in the "ranitidine fiIe" that is referred to in Exhibit 25 (page 179, lines 21-
25).
Please provide us with a time frame within which we can expect to receive these additional
I documents. I look forward to your prompt response.
___p Very truly yours,
em rg ,1.,,,__
E Thomas J. Puppa

Case 1:04-cv-00171-GMS

Document 69-9

Filed 09/28/2005

Page 1 of 3

Case 1:04-cv-00171-GMS

Document 69-9

Filed 09/28/2005

Page 2 of 3

Case 1:04-cv-00171-GMS

Document 69-9

Filed 09/28/2005

Page 3 of 3